Literature DB >> 26845103

New targets for monitoring and therapy in Barth syndrome.

W Reid Thompson1, Brittany DeCroes2, Rebecca McClellan3, Jessica Rubens4, Frédéric M Vaz5, Kara Kristaponis3, Dimitrios Avramopoulos6, Hilary J Vernon3,6.   

Abstract

PURPOSE: Barth syndrome (BTHS), an X-linked disorder caused by defects in TAZ, is the only known single-gene disorder of cardiolipin remodeling. We hypothesized that through analysis of affected individuals, we would gain a better understanding of the range of clinical features and identify targets for monitoring and therapy.
METHODS: We conducted a multidisciplinary investigation involving 42 patients with BTHS, including echocardiograms, muscle strength testing, functional exercise capacity testing, physical activity assessments, cardiolipin analysis, 3-methylglutaconic acid analysis, and review of genotype data. We analyzed data points to provide a quantitative spectrum of disease characteristics and to identify relationships among phenotype, genotype, and relevant metabolites.
RESULTS: Echocardiography revealed considerable variability in cardiac features. By contrast, almost all patients had significantly reduced functional exercise capacity. Multivariate analysis revealed significant relationships between cardiolipin ratio and left ventricular mass and between cardiolipin ratio and functional exercise capacity. We additionally identified genotypes associated with a less severe metabolic and clinical profile.
CONCLUSION: We defined previously unrecognized metabolite/phenotype/genotype relationships, established targets for therapeutic monitoring, and validated avenues for clinical assessment. In addition to providing insight into BTHS, these studies also provide insight into the myriad of multifactorial disorders that converge on the cardiolipin pathway.Genet Med 18 10, 1001-1010.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26845103     DOI: 10.1038/gim.2015.204

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  36 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

Review 2.  Cardiolipin and mitochondrial carriers.

Authors:  Martin Klingenberg
Journal:  Biochim Biophys Acta       Date:  2009-06-17

Review 3.  Cardiolipin, the heart of mitochondrial metabolism.

Authors:  R H Houtkooper; F M Vaz
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

4.  Impaired cardiac reserve and severely diminished skeletal muscle O₂ utilization mediate exercise intolerance in Barth syndrome.

Authors:  Carolyn T Spencer; Barry J Byrne; Randall M Bryant; Renee Margossian; Melissa Maisenbacher; Petar Breitenger; Paul B Benni; Sharon Redfearn; Edward Marcus; W Todd Cade
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-26       Impact factor: 4.733

5.  Six-minute walk test in children and adolescents.

Authors:  Ralf Geiger; Alexander Strasak; Benedikt Treml; Klaus Gasser; Axel Kleinsasser; Victoria Fischer; Harald Geiger; Alexander Loeckinger; Joerg I Stein
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

6.  Severely impaired health status at diagnosis of Pompe disease: a cross-sectional analysis to explore the potential utility of neonatal screening.

Authors:  Tessel Rigter; Stephanie S Weinreich; Carla G van El; Juna M de Vries; Carin M van Gelder; Deniz Güngör; Arnold J J Reuser; Marloes L C Hagemans; Martina C Cornel; Ans T van der Ploeg
Journal:  Mol Genet Metab       Date:  2012-09-21       Impact factor: 4.797

7.  The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study.

Authors:  Amy E Roberts; Connie Nixon; Colin G Steward; Kimberly Gauvreau; Melissa Maisenbacher; Matthew Fletcher; Judith Geva; Barry J Byrne; Carolyn T Spencer
Journal:  Am J Med Genet A       Date:  2012-10-08       Impact factor: 2.802

8.  Barth syndrome: clinical features and confirmation of gene localisation to distal Xq28.

Authors:  L C Adès; A K Gedeon; M J Wilson; M Latham; M W Partington; J C Mulley; J Nelson; K Lui; D O Sillence
Journal:  Am J Med Genet       Date:  1993-02-01

9.  Natural history of Barth syndrome: a national cohort study of 22 patients.

Authors:  Charlotte Rigaud; Anne-Sophie Lebre; Renaud Touraine; Blandine Beaupain; Chris Ottolenghi; Allel Chabli; Helene Ansquer; Hulya Ozsahin; Sylvie Di Filippo; Pascale De Lonlay; Betina Borm; Francois Rivier; Marie-Catherine Vaillant; Michèle Mathieu-Dramard; Alice Goldenberg; Géraldine Viot; Philippe Charron; Marlene Rio; Damien Bonnet; Jean Donadieu
Journal:  Orphanet J Rare Dis       Date:  2013-05-08       Impact factor: 4.123

10.  Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype.

Authors:  Ann Bowron; Julie Honeychurch; Maggie Williams; Beverley Tsai-Goodman; Nicol Clayton; Lucy Jones; Graham J Shortland; Shakeel A Qureshi; Simon J R Heales; Colin G Steward
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

View more
  14 in total

1.  Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study.

Authors:  Adam J Bittel; Kathryn L Bohnert; Dominic N Reeds; Linda R Peterson; Lisa de Las Fuentes; Manuela Corti; Carolyn L Taylor; Barry J Byrne; W Todd Cade
Journal:  JIMD Rep       Date:  2018-04-14

Review 2.  Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.

Authors:  Hana M Zegallai; Grant M Hatch
Journal:  Mol Cell Biochem       Date:  2021-01-07       Impact factor: 3.396

Review 3.  Cardiolipin in Central Nervous System Physiology and Pathology.

Authors:  Caitlin B Pointer; Andis Klegeris
Journal:  Cell Mol Neurobiol       Date:  2016-12-30       Impact factor: 5.046

Review 4.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

5.  Neutropenia in Barth syndrome: characteristics, risks, and management.

Authors:  Colin G Steward; Sarah J Groves; Carolyn T Taylor; Melissa K Maisenbacher; Birgitta Versluys; Ruth A Newbury-Ecob; Hulya Ozsahin; Michaela K Damin; Valerie M Bowen; Katherine R McCurdy; Michael C Mackey; Audrey A Bolyard; David C Dale
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

6.  Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults.

Authors:  Chad Gwaltney; Jonathan Stokes; Anthony Aiudi; Iyar Mazar; Sarah Ollis; Emily Love; Alan Shields
Journal:  Orphanet J Rare Dis       Date:  2021-06-09       Impact factor: 4.123

7.  Impaired cardiac and skeletal muscle bioenergetics in children, adolescents, and young adults with Barth syndrome.

Authors:  Adil Bashir; Kathryn L Bohnert; Dominic N Reeds; Linda R Peterson; Adam J Bittel; Lisa de Las Fuentes; Christina A Pacak; Barry J Byrne; W Todd Cade
Journal:  Physiol Rep       Date:  2017-02

8.  The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.

Authors:  Yan Huang; Corey Powers; Victoria Moore; Caitlin Schafer; Mindong Ren; Colin K L Phoon; Jeanne F James; Alexander V Glukhov; Sabzali Javadov; Frédéric M Vaz; John L Jefferies; Arnold W Strauss; Zaza Khuchua
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

9.  Peak oxygen uptake (VO2peak) across childhood, adolescence and young adulthood in Barth syndrome: Data from cross-sectional and longitudinal studies.

Authors:  William Todd Cade; Kathryn L Bohnert; Dominic N Reeds; Linda R Peterson; Adam J Bittel; Adil Bashir; Barry J Byrne; Carolyn L Taylor
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

10.  Drosophila tafazzin mutants have impaired exercise capacity.

Authors:  Deena Damschroder; Christian Reynolds; Robert Wessells
Journal:  Physiol Rep       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.